Nexterone is owned by Baxter Hlthcare.
Nexterone contains Amiodarone Hydrochloride.
Nexterone has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Nexterone are:
Nexterone was authorised for market use on 24 December, 2008.
Nexterone is available in injectable;injection dosage forms.
The generics of Nexterone are possible to be released after 13 March, 2029.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US6869939||BAXTER HLTHCARE||Formulations containing amiodarone and sulfoalkyl ether cyclodextrin|| |
(10 months ago)
|US7635773||BAXTER HLTHCARE||Sulfoalkyl ether cyclodextrin compositions|| |
(5 years from now)
Drugs and Companies using AMIODARONE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 December, 2008
Korea, Republic of
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic